News AbbVie pays Gubra $350m upfront to enter obesity field AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.
News Boehringer adds to obesity alliance with Denmark’s Gubra Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.
News UK government reveals neighbourhood healthcare delivery plan The UK government's Neighbourhood Health Service is central to the NHS 10 Year Plan - but can it deliver real change?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face